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Abstract
Objectives—The subgenual prefrontal cortex (SGPFC) is an important brain region involved in
emotional regulation and reward mechanisms. Volumetric abnormalities in this region have been
identified in adults with bipolar disorder but thus far not in pediatric cases. We examined the volume
of this brain region in subjects with pediatric bipolar disorder (PBD) and compared them to healthy
controls.
Methods—Fifty one children and adolescents (mean age ± SD; 13.2 ± 2.9 y) with DSM-IV PBD
and 41 (mean age ± SD; 13.7 ± 2.7 y) healthy comparison subjects (HC) underwent 1.5 T structural
magnetic resonance imaging (MRI) brain scans. We traced the SGPFC manually and compared
SGPFC gray matter volumes using analysis of covariance with age, gender, and intracranial volume
as covariates. We also examined the relationship of family history of affective disorders and
medication status to SGPFC volumes.
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Results—SGPFC volumes were not significantly different in PBD and HC subjects. However,
exploratory analysis showed PBD subjects who had one or more first degree relatives with mood
disorders (n = 33) had significantly smaller left hemisphere SGPFC compared to HC (p=0.03 Sidak
corrected). Current usage of a mood stabilizer was significantly associated with larger right SGPFC
volume in PBD (F=4.82, df = 1/41, p=0.03).
Conclusion—Subjects with PBD and a close family history of mood disorders may have smaller
left SGPFC volumes than HC. Mood stabilizing medication may also impact SGPFC size and could
have masked more subtle abnormalities overall.
Keywords
Pediatric bipolar disorder; Subgenual Prefrontal Cortex; Mood stabilizers; Mania; Structural MRI;
emotional regulation
Introduction
The subgenual prefrontal cortex(SGPFC) is an area of the prefrontal cortex ventral to the genu
of the corpus callosum (Drevets et al., 1997). Animal models show it has rich and bidirectional
connections to important emotional regulatory regions including the amygdala, hippocampus,
and parahippocampus (Musil & Olson, 1988). It also projects to subcortical regions including
visceromotoral control neurons such as the nucleus of the solitary tract and spinal autonomic
neurons (Musil et al., 1988). These unique anatomical features suggest an important role in
emotional regulation and mood disorders. In adults metabolic and volumetric deficits in the
SGPFC are associated with depression and abnormal reward mechanisms (Drevets et al.,
1997; Phelps, Delgado, Nearing, & LeDoux, 2004). For example, in unipolar depression
SGPFC exhibits abnormally decreased metabolism, small size, and volumetric changes with
treatment predictive of response to antidepressive medication (Drevets, Ongur, & Price,
1998b; Drevets et al., 1997; Mayberg et al., 2000). In bipolar disorder (BD), SGPFC glucose
metabolism is suppressed in depressed states and activated in manic states suggesting an
important role in the pathophysiology of this condition (Drevets et al., 1997).
Smaller SGPFC volumes are reported in adults with BD but have not been consistently
replicated (Brambilla et al., 2002; Bremner et al., 2002; Drevets, Ongur, & Price, 1998a). One
recent examination of familial and sporadic cases of bipolar disorder did not demonstrate any
differences in the SGPFC from controls(Hajek et al., 2009). This study examined both adults
and adolescents in a single sample which could mask subtle differences given the variable
stages of neurological development. For example the amygdala is shown to be smaller in
bipolar adolescents compared to healthy controls but larger than normal in bipolar adults
(Brambilla, Hatch, & Soares, 2008; DelBello, Zimmerman, Mills, Getz, & Strakowski,
2004). In the only pure pediatric bipolar disorder (PBD) sample studied there were no
significant volumetric deficits in this region seen (Sanches et al., 2005). This may be because
such changes potentially only manifest in adulthood. Other possibilities include insufficient
sample size in previous studies and potential heterogeneity in the PBD phenotype. Most
structural neuroimaging studies to date have been underpowered (Kempton, Geddes, Ettinger,
Williams, & Grasby, 2008). One possible method to raise power is to increase the specificity
of the phenotype. Phenotypic heterogeneity is especially problematic in PBD due to ongoing
debate and uncertainty as to the specific characteristics that constitute PBD (Craney & Geller,
2003; Faedda, Baldessarini, Glovinsky, & Austin, 2004; Kowatch, Youngstrom, Danielyan,
& Findling, 2005; Leibenluft, Charney, Towbin, Bhangoo, & Pine, 2003; Wozniak et al.,
1995).
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We attempted in this study to replicate and expand on earlier efforts to examine morphometric
changes in the SGPFC in PBD subjects. We posited that given an enhanced sample we would
be able to demonstrate similar volumetric brain changes in the SGPFC to those found in adults.
Methods
Child and adolescent subjects aged 7-17 years were recruited through the neuroimaging
research programs at The University of Texas Health Science Center at San Antonio
(UTHSCSA). The Institutional Review Board at UTHSCSA approved this study. Consent was
obtained from the parents and written assent from the subjects for this study. All subjects were
excluded on the basis of serious medical illness, mental retardation (IQ<70), developmental
disorders, or substance abuse within the past 6 months. Inclusion criteria for PBD subjects
included a current DSM-IV diagnosis of bipolar I, II, or NOS. Healthy comparison subjects
were excluded on the presence of any current or past psychiatric disorder in themselves or in
any first degree relative. There was no overlap in the sample population for this study and an
earlier study reported by our group(Sanches et al., 2005).
Assessment
Trained clinicians administered the Kiddie Schedule for Affective Disorders and
Schizophrenia for School-age Children – Present and Lifetime version (K-SADS-PL) to assess
for diagnosis (Kaufman et al., 1997). These clinicians were all M.D. and Ph.D. level in training
and prior to administering the KSADS-PL in this study they achieved 100% inter-rater
agreement on diagnosis of bipolar disorder using this instrument with a board certified child
and adolescent psychiatrist. Final diagnoses were made in a consensus conference with senior
psychiatrists. Family history of psychiatric illness was obtained as part of the initial
examination with a clinician administered form which screened for psychiatric illness in 1st
and 2nd degree relatives. Any major affective disorder (major depressive disorder or BD) in a
first degree relative was considered a positive screen for a family history of mood disorders.
Sociodemographic status was assigned using the Hollingshead Socioeconomic Scale
(Hollingshead Four Factor Index Total Score)(Hollingshead, 1975). IQ was assessed using the
four subtest version of the Wechsler Abbreviated Scale of Intelligence (WASI)(Wechsler,
2001). Pubertal status was assessed using the Peterson Puberty Scale(Peterson, Crockett,
Richards, & Boxer, 1988). Handedness was determined using the Oldfield Handedness
Inventory(Oldfield, 1971).
MRI Acquisition
All subjects were scanned on a 1.5 Tesla Phillips MRI scanner (Phillips Medical System,
Andover, MA). Images were acquired using an axial three-dimensional T1-weighted fast field
echo sequence (field of view 256 mm, view matrix 256X256, repetition time 24ms, echo time
5ms, flip angle 40 degrees, slice thickness 1mm).
Tracing
The brain was first segmented into grey matter, white matter and CSF using the semiautomated
software Brains2 (University of Iowa)(Magnotta et al., 2002). All ROIs were then traced on
the T1-weighted image and over-laid onto the segmented image to obtain grey matter volume.
Total brain volume (TBV) was also traced in coronal plane. Tracing began on the most anterior
slice in which brain matter was visible and continued posteriorly including only brain matter
and excluding CSF, dura mater, sinuses and brainstem, until brain matter was no longer visible.
The base of the cerebellum served as the inferior border The SGPFC was manually traced in
the coronal plane. The borders of the SGPFC were defined rostrally as gray matter of the first
full gyrus below the corpus callosum and caudally to the slice anterior to where the internal
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capsule no longer divided the striatum. All of the tracings were performed by the same M.D.
level technician who was blind to the diagnosis. This technician was trained in the method
previously utilized by our group and described in detail in an earlier manuscript (Brambilla et
al., 2002).
Data Analysis
Statistical analyses were conducted using SPSS for Windows version 15.0 (SPSS Inc., Chicago,
Ill.). Samples were compared on demographic variables using independent sample t-tests and
chi square tests. SGPFC volumes of HC and PBD subjects were compared using analysis of
covariance (ANCOVA) with age, gender, and total brain volume as covariates. We tested the
effects of a narrowly defined BD diagnoses (excluding BD NOS), comorbid ADHD,
medication and family history using ANCOVA and pairwise comparisons with Sidak
correction for multiple comparisons where appropriate. All tests were two-sided with
significance defined at the p <0.05 level.
Results
Fifty-one subjects met eligibility and exclusion criteria for DSM-IV PBD and 41 met criteria
for HC (A.P.A., 1994). Further demographic details are available in table 1. The two groups
were similar demographically except for a greater proportion of Hispanic subjects in the HC
group.
There was no statistically significant difference in total left or right SGPFC gray matter
volumes between subjects with PBD and HC (table 2). Due to our concern about the impact
of phenotypic heterogeneity of PBD on our ability to detect differences in SGPFC volume we
conducted a planned analysis excluding all BD NOS subjects. In this analysis the left SGPFC
volume (df=1/83, F=4.38, p=.04) but not the right SGPFC was significantly smaller in PBD
subjects.
Dividing the PBD subjects into subgroups according to whether or not they had one or more
first degree relatives with any mood disorder revealed the subjects with a positive family history
(n = 33; 18 with family history of unipolar depression, 15 with bipolar disorder) had
significantly smaller left SGPFC volumes compared to those with a negative family history (n
= 18, p=0.05 Sidak corrected), and compared to the HC (n = 41, p = 0.03 Sidak corrected).
There were no significant differences among the three groups with respect to right SGPFC
volumes (table 3).
Given that ADHD was a highly co-morbid condition in our PBD sample (table 1), we examined
the effect of ADHD diagnosis on SGPFC. ADHD status was not significantly associated with
SGPFC volumes (Table 4).
Of 36 subjects with PBD who were on medication at that time of the study 8 were using a mood
stabilizer, 6 antipsychotics, 11 antidepressants, and 6 stimulants. Subjects that were currently
taking psychotropic medications (n = 36) did not differ significantly from those that were not
taking such medications (n = 15) with respect to left (p = 0.99) or right (p = 0.61) SGPFC
volume. Those PBD subjects that were using mood stabilizers (n = 8), compared to those who
were not (n = 43), had significantly larger right (p = 0.01) but not left (p = 0.50) SGPFC
volumes. The effects of antipsychotics were similar (n = 6 taking antipsychotics versus n = 45
not taking them) and approached significance for right (p = 0.05) but not left (p = 0.96) SGPFC
volume.
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Our primary comparison of SGPFC size between diagnostic groups did not demonstrate
significance. This is similar to an earlier finding by our group reported with a smaller sample
(Sanches et al., 2005). After excluding BD NOS subjects we found significantly smaller left
but not right SGPFC volumes in PBD subjects in comparison to healthy subjects. This line of
reasoning is similar to our neurocognitive findings with this sample (Glahn et al., 2005). Those
results suggested that findings in these regions are not detectable in samples using a broader
phenotype. Other researchers have separated out children with chronic irritability from the
PBD phenotype and have classified such cases as having a novel diagnosis called severe mood
dysregulation (Brotman et al., 2006). Some also emphasize the importance of “cardinal”
features of BD namely grandiosity and elation (Geller, Tillman, Craney, & Bolhofner, 2004).
The current study design does not enable us to examine these controversies directly. Our study
findings suggest, however, that the different PBD subtypes may have varied pathogenic
mechanisms and that these differences could have implications on brain structure.
We conducted another exploratory analysis after assigning PBD subjects to subgroups
according to whether they had a family history of mood disorders. The left but not right SGPFC
was significantly smaller in familial cases of PBD compared to both non-familial PBD and HC
subjects. Given the high degree of heritability of BD, the presence of a positive family history
of mood disorder in a first degree relative may increase the specificity of the diagnosis and the
power to detect differences (McGuffin et al., 2003; Sharma et al., 2003). Taken together our
findings support the hypothesis that increasing the specificity of the PBD phenotype increased
the ability to detect SGPFC volume differences.
Only one previous study has examined the volume of the SGPFC in PBD. In that study Sanches
et al. did not find any difference in the SGPFC volume of PBD compared to HC subjects. They
also examined PBD subjects with familial BD and did not find any significant results (Sanches
et al., 2005). Our study is in agreement with the main finding of the Sanches et al. study in that
we were not able to detect differences in SGPFC size in the overall sample comparing PBD to
HC subjects. It is possible that the SGPFC differences reported in adults with BD are not present
early on in childhood. Another possibility is that they are present in only certain subtypes of
PBD or in high risk populations. Medication usage is also an important variable to consider.
Our post hoc analysis of the influence of medication in our sample indicated that their use may
have masked or reversed possible disease related changes by enlarging gray matter in treated
subjects. This correlates well with previous literature documenting the impact of mood
stabilizers and in particular lithium on increasing gray matter (Bearden et al., 2007; Monkul
et al., 2007; Sassi et al., 2002). One of the important limitations of this study than is that it is
a cross sectional study with a heterogeneous mixture of medicated and unmedicated subjects.
We therefore do not know whether these subjects had these changes prior to disease expression
or medication exposure. Our study was also not designed to adequately examine the differences
between PBD subtypes with regards to “cardinal symptoms” or in relation to chronic versus
episodic irritability. Future studies should consider investigating more specifically the
significance of these phenotypic patterns of BD on brain structure. Longitudinal studies could
help to parse out the role of normal brain maturation, disease trait and state related changes,
and medication effects on brain morphometry. Ultimately these types of studies could improve
our understanding of the pathogenesis of BD and identify more specific opportunities for early
intervention and prevention.
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Tracing of the SGPFC in the Coronal Plane
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Saggital View of the SGPFC
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Table 1
Demographic and Clinical Variables
HC (n=41) PBD (n=51) p
Mean (SD) Mean (SD)
Age in y 13.7 (2.7) 13.2 (2.9) 0.41
SES 45.0(14.0) 43.6 (14.3) 0.68
Puberty Score 2.52(1.0) 2.35(1.2) 0.45
N (%) N (%)
Male 21 (51.2) 28 (54.9) 0.83
Caucasian 6 (14.6) 33 (64.7) <0.01
Hispanic 29 (70.7) 14 (27.5) <0.01
Right Handed 36 (90) 46 (90.2) 0.36
ADHD n/a 31 (58.5)
Anxiety Disorders n/a 33 (62.3)
Disruptive Behavior Disorders n/a 24 (45.3)
Bipolar I Disorder n/a 29 (56.9)
Bipolar II Disorder n/a 15 (29.4)
Bipolar Disorder NOS n/a 7 (13.7)
Ever taken Psychiatric Medication 1 (2.4) 41 (80.4)
Currently taking psychiatric medication 1 (2.4) 36 (70.6)
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Table 2
SGPFC Comparison by Diagnostic Group
HC PBD p**
Mean (SD) Mean (SD)
R. SGPFC* 347(125) 322(121) 0.34
L. SGPFC* 400(144) 350(126) 0.09
*
All units are mm3
**
ANCOVA with age, gender, TBV as covariates
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Table 3
Comparison of SGPFC volumes as a function of having a first degree relative with any mood disorder
HC (n = 41) PBD with positive family history (n = 33) PBD with negative family history (n=18) p**
Mean (SD) Mean (SD) Mean (SD)
R. SGPFC* 347(125) 318(126) 331(116) 0.62
L. SGPFC* 400(144) 318(120) 409(118) 0.01
*
All units are mm3
**
ANCOVA with age, gender, TBV as covariates. For L SGPFC, pairwise comparisons using Sidak correction for multiple comparisons showed that
mean volume of HC was significantly larger than that of PBD with positive family history (p = .027). Remaining pairwise differences were not
significant.
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Table 4
SGPFC in PBD with comorbid ADHD
ADHD (n=31) No ADHD (n=20) p**
Mean (SD) Mean (SD)
R. SGPFC* 327(115) 315(133) 0.76
L. SGPFC* 327(113) 386(138) 0.07
*
All units are mmˆ3
**
ANCOVA with age, gender, TBV as covariates
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